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ABSTRACT19
We studied the transcriptomic response of Streptococcus pneumoniae to levofloxacin,20
under conditions inhibiting topoisomerase IV, but not gyrase. Although a complex21
transcriptomic response was observed, the most outstanding result was the up-22
regulation of the genes of fatDCEB operon, involved in iron (Fe2+ and Fe3+) uptake,23
which were the only genes varying at every condition tested. Although the inhibition24
of topoisomerase IV by levofloxacin did not have a detectable effect in the level of25
global supercoiling, increases in general supercoiling and fatD transcription were26
observed after topoisomerase I inhibition, while the opposite was observed after27
gyrase inhibition with novobiocin. Since fatDCEB is located in a topological28
chromosomal domain down-regulated by DNA relaxation, we studied the29
transcription of a copy of the 422-bp (including the Pfat promoter) region located30
upstream of fatDCEB fused to the cat reporter inserted into the chromosome 106-kb31
away from its native position: PfatfatD was up-regulated in the presence of LVX in its32
native location, whereas no change was observed in the Pfatcat construction. Results33
suggest that topological changes are indeed involved in PfatfatDCE transcription. Up-34
regulation of fatDCEB would lead to an increase of intracellular iron, and in turn, to35
the activation of the Fenton reaction and the increase of reactive oxygen species. In36
accordance, we observed an attenuation of levofloxacin lethality in iron-deficient37
media and in a strain lacking the gene coding for SpxB, the main source of hydrogen38
peroxide. In addition, we observed an increase of reactive oxygen species that39
contributed to levofloxacin lethality.40
41
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Streptococcus pneumoniae (the pneumococcus) acts as an opportunistic pathogen. It forms42
part of the commensal microbiota of the human nasopharynx. Under specific43
circumstances, it migrates to other niches (ear, lung, bloodstream, cerebrospinal fluid)44
causing diverse pathologies. One million children aged <5 years die annually of45
pneumococcal infections worldwide (1). After the usage of the pneumococcal 7-valent46
conjugate vaccine, which includes the serotypes more often associated with resistance to47
antibiotics, the incidence of invasive pneumococcal disease declined (2, 3) coincidentally48
with a decrease of penicillin resistance rates in many countries (3-5). However, emergence49
of serotypes not included in the vaccine has been observed (6, 7). Therefore, knowledge of50
the molecular bases of antimicrobial action, including the mechanisms of killing, is51
essential for developing improved therapeutics.52
Resistance in S. pneumoniae to antibiotics acting either in cell wall (beta-lactams) or53
protein synthesis (macrolides) has spread worldwide in the last three decades (8). The54
fluoroquinolones (FQs) levofloxacin (LVX) and moxifloxacin are used nowadays for55
treatment of adult patients with pneumonia. FQ-resistance in S. pneumoniae is maintained56
at low prevalence (< 3%) in Europe (9, 10), although higher rates have been detected in57
Asia (11) and in Canada (12). However, an increase in resistance in this bacterium may58
occur if FQ use is increased (13). FQs target the type II DNA topoisomerases. Despite the59
functional similarities between topoisomerase (topo) IV and gyrase, their susceptibility to60
FQs varies across bacterial species (14). In S. pneumoniae, the primary target for LVX is61
topo IV (15-18), while gyrase is the primary target for moxifloxacin (19). Type II62
topoisomerases maintain DNA topology and solve the topological problems associated with63
DNA replication, transcription, and recombination (20). Gyrase introduces negative64
supercoils into DNA (21) whereas topo IV relaxes DNA and participates in chromosome65
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partitioning (22). Chromosomal topology in Escherichia coli is maintained homeostatically66
by the opposing activities of topoisomerases which relax DNA (topo I and topo IV), and by67
gyrase. In these bacterium, transcription of the topA gene encoding topo I increases when68
negative supercoiling increases (23), while that of gyrA and gyrB increases after DNA69
relaxation (24-26). Changes in DNA supercoiling also have a global effect on genome70
transcription in E. coli (27, 28) and Haemophilus influenzae (29). We have also shown that71
relaxation of the S. pneumoniae chromosome with novobiocin (NOV, a GyrB inhibitor)72
causes up-regulation of gyrase genes and down-regulation of topo I and IV genes, and73
triggers a global transcriptional response affecting ca. 14% of the genome (30). Most74
(>68%) responsive genes are closely positioned forming 15 gene clusters (up- and down-75
regulated topological domains), which showed a coordinated response (30).76
The killing effect of FQs has been related to the resolution of reaction intermediates of77
DNA-FQ-topoisomerase complexes, which generates irreparable double-stranded DNA78
breaks (31). This could occur in E. coli by two pathways, one dependent on protein79
synthesis and the other independent. It has been shown that hydroxyl radical action80
contributes to FQ-mediated cell death occurring via a protein-dependent pathway (32). This81
result agrees with a recently proposal suggesting that, following gyrase poisoning, hydroxyl82
radical formation utilizing internal iron and the Fenton reaction (33) are generated and83
contributes to cell killing by FQs (34) as well as by other bactericidal antibiotics (35, 36).84
In this mechanism, proposed for Enterobacteriaceae (35, 37), the primary drug-interactions85
stimulate oxidation of NADH via the electron transport chain that is dependent of the86
tricarboxylic acid cycle. Hyperactivation of the electron transport chain stimulates87
superoxide formation. Superoxide destabilizes the iron-sulfur clusters of enzymes, making88
Fe2+ available for oxidation by the Fenton reaction. The Fenton reaction leads to the89
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formation of hydroxyl radicals that would damage DNA, proteins and lipids (38), which90
results in cell death. Instead a generalized oxidative damage, a recent study supports that91
the main action of hydroxyl radicals is the oxidation of guanine (to 8-oxo-guanine) of92
nucleotide pool. The incomplete repair of closely spaced 8-oxo-deoxyguanosine lesions93
caused lethal double-strand DNA breaks, which would underlie much of the cell death94
caused by beta-lactams and FQs (39). However, recent investigations have questioned the95
role of hydroxyl radicals and intracellular iron levels in antibiotic-mediated lethality using96
either similar antibiotic concentrations (40) or higher concentrations (41) than used97
previously. The disparate results obtained using diverse antibiotic concentrations and times98
of treatment emphasize the complexity of the lethal stress response (42).99
Given that different antibiotic families have different intracellular targets, it is essential100
to know the pathway between the initial antibiotic-target interaction and the promotion of101
hydroxyl radical formation. These pathways are mostly unknown. A model has been102
proposed for aminoglycosides in E. coli in which, the interference of these drugs with103
ribosome progression would release incomplete polypeptides, which are translocated to the104
cell membranes where they may trigger envelope stress. The Arc regulatory system is105
perturbed, accelerating respiration and thereby increasing the flux of superoxide and106
hydrogen peroxide into the cell (43). However, for FQs, the specific pathway has not been107
established, although a general scheme for stress-response regulation in E. coli, which108
involves the hydroxyl radical cascade, has been proposed (42). The present study was109
aimed to understand the transcriptional response to levofloxacin in S. pneumoniae at110
concentrations that inhibited its primary target, topo IV, without inhibiting gyrase, to avoid111
the opposite effects of these two enzymes on DNA topology. Changes in DNA topology112
were tested by analyzing the distribution of topoisomers of a replicating plasmid. Global113
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transcription response was analyzed using microarrays technology after cells’ exposure to114
two LVX concentrations. Microarray data were validated by quantitative real-time PCR115
(qRT-PCR). In addition, transcriptional regulation of the fatDCEB operon, coding for an116
iron transporter was analyzed. The relation between iron transport and lethality was also117
tested. Results provide a pathway between topo IV inhibition and hydroxyl radical118
production and suggest that S. pneumoniae uses iron accumulation as part of the death119
process associated with LVX treatment.120
MATERIALS AND METHODS121
Bacterial strains, growth and transformation of bacteria. S. pneumoniae was grown in122
AGCH medium with 0.3% sucrose and transformed as described previously (44). MICs of123
LVX (Sigma) and chloramphenicol (CHL) for R6 strain were 0.25 g/ml and 1.25 g/ml,124
respectively. To construct the spxB strain, two fragments of 1481 bp and 1374 bp flanking125
spxB were amplified with oligonucleotide pairs SpxBUPF1/SpxBUPR1 and126
SpxBDOWNF1/SpxBDOWNR1 (Table S1), digested with SphI and XbaI and ligated to the127
CHL-acetyl transferase gene (cat) of plasmid pJS3 digested with the same enzymes. R6128
was transformed; recombinant colonies were selected in medium containing 2.5 g/ml129
CHL and checked by PCR amplification with external oligonucleotides130
SpxBUPF2/SpxBDOWNR2 (Table S1). Those with the appropriate size (4574 bp versus131
5352 bp of R6) were sequenced using oligonucleotide CATMED. To construct the R6-132
Pfatcat strain, five PCR products were obtained. Two from genes spr1793 (1061 bp) and133
spr1794 (1036 bp), flanking the site of insertion, by amplifications with primers134
1793F1(XbaI)/spr1793R1 and spr1794F1/spr1794R1(SphI). The third fragment (144 bp),135
was amplified with UptrcatXba/UptrcatEco, and contains the transcriptional terminator that136
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precedes the cat cassette in plasmid pJS3. The fourth fragment (422 bp) containing the 5´-137
upstream region of the iron transport operon fatDCEB was amplified with138
UpfatDF1(EcoRI) and phosphorylated UpFatDR1. The fifth fragment (758 bp) contains cat139
and was amplified with Cat1 phosphorylated and CatDownSph(SphI). Each fragment was140
digested with the appropriate enzyme, and all fragments ligated together. The ligation mix141
was used to transform strain R6, and transformants selected in medium containing 2.5142
g/ml CHL. This rendered strain R6-Pfatcat (Fig. 3A), whose genetic structure was checked143
by PCR with primers Spr1793R2 and Spr1794F2, and by sequencing with CATMED,144
CAT191, and spr1793R3.145
Analysis of the topology of covalently closed circles. Plasmid DNA isolation from S.146
pneumoniae cultures grown on AGCH medium with 1 /g/ml tetracycline (for147
pLS1selection) was performed as described before (30). Circular DNA molecules were148
analyzed in neutral/neutral two-dimensional agarose gels, which were subjected to149
Southern hybridization with a 240-bp specific pLS1 probe as described previously (30).150
DNA linking number (Lk) was calculated by quantifying the amount of every topoisomer.151
DNA supercoiling density () was calculated from the equation  = Lk/ Lk0. Linking152
number differences (Lk) were determined using the equation Lk = Lk  Lk0, in which Lk0153
= N/10.5, where N is the size of the molecule (in bp) and 10.5 the number of bp per one154
complete turn in B-DNA.155
RNA extraction and real time RT-PCR experiments. Synthesis of cDNAs from 5 g156
of total RNA was performed as previously described (52). These cDNAs were subjected to157
quantitative qRT-PCR (Chromo 4, BioRad) in 20 l reactions containing 2 l of cDNA, 0.3158
M of each specific primer, and 10 l of LightCycler FastStart Universal A SYBR Green159
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Master (Roche). Amplification was achieved with 42 cycles of a tree-segment program:160
denaturation (30 s at 94°C), annealing (30 s at 45–56°C), and elongation (30 s at 68°C). To161
normalize the three independent cDNA replicate samples, values were divided by those162
obtained of the amplification of internal fragments of rpoB (52) and 16S rDNA. The163
oligonucleotides used are shown in Table S1.164
Microarray data normalization and analysis. High density arrays A6701-00-01 from165
Roche NimbleGen were used. Double-stranded cDNAs were obtained from total RNA with166
the SuperScriptTM Double-Stranded cDNA Synthesis Kit (Invitrogen). Labeling of cDNAs167
with Cy3 and hybridization were performed at the Institut de Recerca Biomèdica,168
Barcelona (Spain). A GenePix 4000B scanner at 5 µm resolution was used and raw data169
were extracted and RMA normalized using NimbleScan v2.4. After this normalization,170
Partek Genomics Suite 6.4 was used to do a principal component analysis and test for171
significance for differential gene expression using ANOVA. Each microarray experiment172
was carried out in duplicate with cDNA prepared from two independent cultures. All173
microarray data are available at the Array Express (EBI, UK) database via accession174
number E-MEXP-3809.175
Detection of reactive oxygen species. The intracellular oxidation levels were measured176
using dihydrorhodamine 123 dye (Sigma-Aldrich), a non-fluorescent compound which177
diffuses passively across membranes. Oxidation converts it to the fluorescent product178
rhodamine 123, and this fluorescence is proportional to the level of oxidation (37). In a179
typical experiment, cells were grown exponentially to an optical density at 620 nm (OD620)180
= 0.4 before LVX was added. One ml samples were collected, cells were washed once in181
500 l of 1 PBS (pH 7.2) and suspended in 250 l of 1 PBS containing 2.5 g/ml of182
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dihydrorhodamine 123 and incubated at 37°C in the dark for 30 min. Cells were washed183
once in 500 l of 1 PBS and suspended in 250 l of 1 PBS. A volume of 200 l was184
used to measure fluorescence. The fluorescence signal was analyzed using a Tecan Infinite185
2000 with excitation /emission  of 485 nm/535 nm. Results were expressed as relative186
fluorescence units (RFU) and were normalized according to the number of live cells at each187
time point (45).188
RESULTS189
DNA topoisomer distribution did not vary under treatment with LVX. The effect of190
LVX was tested in the reference strain R6 carrying plasmid pLS1 at subinhibitory (0.5191
MIC) and fully inhibitory (10 MIC) concentrations. The change in OD260 along the 60 min192
of the experiment was from 0.4 to 0.8. Cell division was inhibited only when the culture193
was treated with LVX at 10 MIC, with decreases in cell viability to about 70% and 97% at194
30 and 60 min, respectively (Fig. 1A). To measure supercoiling alterations, topoisomer195
distributions of the replicating pLS1 plasmid were analyzed. Under the chloroquine196
concentration used, the induced Lk is 14 (40). Topoisomers appeared distributed in the197
autoradiograms in a bubble-shaped arc, where negative and positive supercoiled molecules198
are located to the right- or to the left-side, respectively (Fig. 1B). Although we have not199
measured the supercoiling level of the bacterial chromosome, the values obtained on small200
plasmids provide a good estimation of chromosomal supercoiling (46). No significant201
differences in supercoiling densities () were detected in any condition, showing that the202
inhibition of topo IV by LVX did not have a detectable effect in the level of global203
supercoiling and that gyrase was not inhibited at the LVX concentrations used.204
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Two kinds of transcriptional responses in LVX-treated cultures: growth-related,205
LVX-related. The transcriptional response was measured in cultures of strain R6 at three206
time points (5, 15, and 30 min) after treatment with LVX concentrations of 0.5 MIC and207
10 MIC. In addition, samples taken at 15 and 30 min of an untreated culture (No-LVX)208
were also analyzed and used to distinguish those genes varying along the growth curve.209
Only gene expression variations 2 (P values <0.01) with respect to time 0 min were210
considered. The whole transcriptomic response is shown in Table 1. Based on the results211
obtained, responsive genes were classified into two categories: growth-related and LVX-212
related (Fig. 2, Table 1). Growth-related genes included 108 genes showing transcription213
variations in the No-LVX culture. Additionally, 10 genes forming part of operons with214
these genes were also considered to be growth-related. In total, 118 genes (5.8% of the215
genome), showed variations associated with growth (Fig. 2A).216
Genes controlled by two-component systems (TCS)-12 and -13 represented the greatest217
proportion (50.8%) of responsive genes (Table 1, Fig. 2C). TCS-12 regulates competence218
for genetic transformation (47). The regulatory cascade begins with the secretion and219
processing of ComC by the dedicated ABC transporter ComAB. Processed ComC activates220
TCS-12 ComDE: ComD is the histidine kinase (that senses the stimulus), ComE is the221
response regulator (the transcriptional modulator of the responsive genes). Phosphorylated222
ComE activates the transcription of early genes, including the alternative sigma factor223
ComX (48), which activates transcription of late competence genes (49, 50). Among224
competence genes, 53 (11 early and 42 late genes) showed down-regulation. These225
included most (10 out of 18) genes of the early competence response (49), which are226
transcribed from 7 out of the 10 promoters (Table 1) containing the binding site of the227
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transcriptional activator ComE (51). Early down-regulated genes included those coding for228
the two transcriptional regulators of competence, comE and two genes coding for the229
alternative sigma factor ComX (52), required for induction of many late genes. In230
accordance, 42 out of the 81 late-competence genes (49) were down-regulated. These 42231
genes were transcribed from 13 out of 19 promoters containing a ComX box. Concerning232
TCS-13 (SpiRH), 13 genes containing regulatory sequences for its response regulator SipR233
(53, 54) were up-regulated, including spiP encoding the bacteriocin with a Gly-Gly motif234
and the dedicated ABC transporter (spiABCD).235
The LVX-related response involved 108 out of 174 genes that did not show236
variations in the No-LVX culture (Fig. 2B). Of them, 4 vary only at 5 min after 10 MIC237
treatment. Among LVX-responsive genes, 24.1% code for hypothetical proteins, and the238
same proportion for transport proteins (Fig. 2C). Interestingly, the only genes up-regulated239
at 5 min in 0.5 MIC were the four genes of the fatDCEB operon (55). These genes were240
up-regulated at every time and LVX concentration used. We have previously shown that241
the fatDCEB operon is located in a topological domain (D14, Fig. 3A) showing down-242
regulation under NOV treatment, as tested by microarray experiments (30). We validated243
these results by qRT-PCR, showing that treatment with NOV caused a decrease in fatD244
transcription at any time tested at 10 MIC, and at 5 min at 0.5 MIC. At 0.5 MIC, a245
recovery in fatDCE transcription was observed (Fig. 3B), as expected from the general246
supercoiling recovery (30). On the contrary, qRT-PCR confirmed the up-regulation of247
fatDCEB at all times regardless of LVX concentration (Fig. 3C), with similar fold-variation248
values that in microarrays. To test the role of topo IV inhibition in the up-regulation of249
fatD, qRT-PCR determinations in a LVX-resistant R6 mutant containing a ParCS79F250
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change in topo IV (56), treated with the same LVX concentrations that R6, were performed.251
No increase of fatD transcription in this strain was observed.252
fatDCEB transcription is affected by supercoiling levels. Even when no changes in the253
general supercoiling levels were detected in the presence of LVX (Fig. 1C), we assumed254
that local changes in supercoiling could be involved in the regulation of the fatDCEB255
operon. To check this possibility, a strain (R6-Pfatcat in Fig. 3A), which contains a 422-bp256
region located upstream of fatDCEB that includes the promoter of the operon (Pfat), fused to257
the cat reporter gene, was inserted into the chromosome 106 kb away from fatDCEB (Fig258
3A). The levels of transcription of fatD and cat were tested by qRT-PCR in cultures treated259
with two LVX concentrations (Fig. 3C). While fatD showed up-regulation in the presence260
of LVX, almost no change was observed in cat transcription. Thus, supercoiling alteration261
induced by LVX is acting as a regulator of Pfat, given that its transcriptional up-regulation is262
dependent on its location in a topological chromosomal domain.263
In addition, the level of transcription of fatDCEB was tested by qRT-PCR in264
cultures treated either with NOV, an inhibitor of GyrB (21, 57) (Fig. 3B) or with N-methly-265
seconeolitsine (a topo I inhibitor) (58). Treatment with N-methly-seconeolitsine caused, as266
expected (58), a general increase in supercoiling (Fig. 4A). This increase was accompanied267
by a rise in the transcription of fatD and fatC at every concentration tested (Fig. 4B).268
Transcriptional activation of iron transport induced by LVX is involved in cell269
death. The increase in transcription of the fatDCEB operon would lead to the accumulation270
of toxic concentrations of iron within the cell. This toxicity would be related to the271
activation of the Fenton reaction, which utilizes unincorporated intracellular iron and272
transfers an electron to hydrogen peroxide (Fig. 5A). To test if intracellular iron is an273
important component of the LVX-mediated killing, R6 was grown in the presence of LVX274
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in three different media: AGCH (containing 1.58 M of SO4Fe); AGCH plus the iron275
chelator o-phenantroline, or AGCH deficient in SO4Fe (AGCH*). Attenuation of the276
bactericidal effect of LVX, both in AGCH + o-phenantroline and in AGCH*, was277
observed, suggesting a role for intracellular iron in LVX lethality (Fig. 5B).278
The main source of endogenous hydrogen peroxide in S. pneumoniae is SpxB (59), the279
pyruvate oxidase enzyme (EC 1.2.3.3) which decarboxylates pyruvate to acetyl phosphate280
plus H2O2 and CO2 (Fig. 5A). To assess that LVX lethality was related to the production of281
hydroxyl radicals via the Fenton reaction, a SpxB-deletion mutant was constructed as282
detailed in Material and Methods. The spxB strain was less susceptible to the killing by283
LVX, the attenuation being similar to that exhibited by R6 grown either in the presence of284
o-phenantroline or in AGCH* (Fig. 5B). These results provided a relation between LVX285
lethality and the Fenton reaction via the increase of intracellular iron. In addition,286
accumulation of reactive oxygen species was measured by the oxidation of287
dihydrorhodamine 123. Accumulation was observed in R6 cultures treated with LVX (Fig.288
5C), with increases with respect to time 0 min higher than 35-fold at 3, 4, and 5 h of289
treatment. Similar increases in reactive oxygen species had been observed in ciprofloxacin-290
treated S. pneumoniae with a different dye probe (45), and also in norfloxacin-treated E.291
coli (35). This accumulation was reverted about 10-fold by o-phenantroline. A similar292
reversion was observed in the spxB strain.293
DISCUSSION294
The complex transcriptional response observed in our microarray experiments lead295
us to differentiate among those genes whose transcription was altered as a consequence of296
growth and those that were LVX-dependent. We detected that 5.8% of the genome varied297
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as a consequence of growth, involving mainly genes of two of the 13 pneumococcal two-298
component-systems, TCS-12 and -13. The major response corresponded to genes dependent299
of TCS-12 (ComDE), involved in the regulation of competence for genetic transformation.300
However, in the presence of LVX, competence genes showed decreases in transcription301
lower ( ± 0.8, average ± SD) than those observed at 30 min in the untreated culture.302
These results suggest that two opposed regulation mechanisms are acting over competence303
development in the LVX-treated cultures: the growth-phase caused down-regulation of304
competence genes, while LVX counteracted this down-regulation. These results are in305
agreement with the described transcriptional activation of ssbB, a late competence gene,306
after 2.5 hours of FQ treatment, with the subsequent induction of transformability (60).307
Thus, in response to FQs, S. pneumoniae, a bacterium lacking an SOS-like system,308
activates the competence regulon, supporting the hypothesis that competence is a general309
stress response of S. pneumoniae (60). Conversely, the up-regulation of the genes310
controlled by TCS-13 (SpiRH) was not affected by LVX treatment.311
The LVX-related response included 108 genes (5.2% of the genome). The most striking312
result in the LVX response was the up-regulation of the fatDCEB operon at the earliest time313
analyzed (5 min) and at the subinhibitory (0.5 MIC) concentration, being the only genes314
varying in this condition. We tested fatD transcription in a LVX-resistant R6 mutant and no315
up-regulation was observed in the presence of the antibiotic (Fig. 3). These results indicate316
that the LVX transcriptional effects were indeed due to the inhibition of topo IV. However,317
changes in the general supercoiling levels in the presence of LVX were not found (Fig. 1C).318
Likewise, no changes in general chromosomal supercoiling were observed in E. coli cells319
treated with oxolinic acid, an inhibitor of gyrase (61).We assumed that local changes in320
15
supercoiling could be involved in the regulation of fatDCEB. To test the role of321
supercoiling in fatDC transcription, we altered global supercoiling in both directions. On322
one side, we increased global supercoiling by using the DNA topo I inhinitor N-methly-323
seconeolitsine (58). On the other, we decreased supercoiling by using the gyrase B inhibitor324
NOV (57). We observed both an increase in supercoiling (Fig. 4A) and of fatDC325
transcription with the topo I inhibitor (Fig. 4B). On the contrary, treatment with NOV326
caused a decrease in fatDC transcription, as detected by qRT-PCR (Fig. 4C), in accordance327
with a general supercoiling decrease and down-regulation of fatDCE transcription in328
microarrays (30). Microarrays results have shown that fatDCEB is located in topological329
cluster D14, which contains genes down-regulated when DNA supercoiling decreases (30).330
We constructed a strain with a copy of the 422-bp fatDCEB-upstream region fused to cat331
inserted 106-kb away from its native position. Transcription from Pfat in the presence of332
LVX varied depending on its chromosomal location. It was up-regulated in its appropriate333
chromosomal location in down-regulated cluster D14, but was almost not regulated when334
located 106 kb away (Fig. 3), in a non-regulated domain.335
Besides this supercoiling regulation, the fatDCE operon has been shown to be regulated336
in several ways, as expected for an operon essential for iron homeostasis. Among them,337
environmental factors, such as high levels of extracellular Mn2+ (62) and low pH (63)338
caused its transcriptional up-regulation, whereas aerobiosis caused its down-regulation339
(64). Other regulators of the operon are the RitR repressor and (55) the CodY repressor,340
whose DNA binding capacity is modulated by branched chain amino acids (65, 66). In341
accordance, we observed codY down-regulation in the LVX response (Table 1), probably342
contributing to the up-regulation of fatDCEB.343
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The genome of S. pneumoniae R6 encodes three operons for iron transport systems344
(spr0224–spr0220, spr0934–spr0936, and fatDCEB). Out of them, only fatDCEB is345
involved in iron (Fe2+ and Fe3+) uptake (67). In this way, the up-regulation of the operon346
would cause an increased uptake of iron and its intracellular accumulation, which in turn347
would activate the Fenton reaction (Fig. 5A). We have observed attenuation of the LVX348
bactericidal effect in media defective in iron (Fig. 5B), confirming that intracellular iron is349
a component of LVX-mediated killing. In addition, the accumulation of reactive oxygen350
species (Fig. 5C) was in accordance with this interpretation. These results agree with the351
proposed mechanism of killing by bactericidal antibiotics, including FQs (35). The352
stimulation of the Fenton reaction is the final common step. However, there are several353
differences between this model and the one we propose in this study (Fig. 6). S.354
pneumoniae is a lactic acid bacterium that obtains its metabolic energy exclusively from the355
fermentation of carbohydrates via glycolysis. Its genome does not contain genes for the356
tricarboxylic acid cycle, and lacks the cytochromes and heme-containing proteins involved357
in aerobic respiration. In addition, although genes coding the F0F1-ATPase, are present, this358
proton pump does not synthesize ATP; conversely, it works at the expense of ATP, and359
serves as the major regulator of intracellular pH (68). Consequently, the only enzymes360
annotated as iron-sulfur-dependent in the S. pneumoniae R6 genome are the two subunits of361
the L-Ser dehydratase (Spr0094 and Spr0095). The main reason for the increase of362
intracellular Fe2+ in the presence of LVX should be transcriptional activation of the363
fatDCEB transporter. The importance of iron in the susceptibility to antibiotics has been364
recently reinforced by the demonstration that overexpression of an iron efflux system in365
Salmonella typhimurium protects cells against ampicillin and ciprofloxacin (69). With366
respect to the other component of the Fenton reaction —hydrogen peroxide— it is mainly367
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produced in S. pneumoniae by the SpxB enzyme (59, 70). We deleted the gene encoding368
this enzyme (spxB) and observed that this strain was more resistant to the killing by LVX369
than its spxB+ parental strain, the attenuation being similar to that exhibited by R6 grown in370
iron-deficient media (Fig. 5B). The difference in lethality between the wild-type R6 strain371
and the R6-spxB mutant in the presence of 2.5  MIC LVX was in the same range to that372
observed between E. coli wild-type and mutant strains lacking either superoxide dismutase373
activities (36) or both catalase and peroxidase activities (36, 40), which accumulate H2O2,374
in the presence of norfloxacin at 4- to 10  MIC. We have observed protection to FQ375
lethality using low LVX concentrations (2.5  MIC), in agreement with results of E. coli376
treatment with norfloxacin at 2  to 4  MIC (41). In conclusion, we have shown for the377
first time that fatDCEB transcription is regulated by supercoiling level. The primary effect378
of the interaction of LVX-topo IV is the up-regulation of the operon by local increase in379
DNA supercoiling. This up-regulation would increase the intracellular level of iron, which380
activates the Fenton reaction, increasing the concentration of hydroxyl radicals. These381
effects were observed before the inhibition of protein synthesis mediated by LVX. All these382
effects, together with the DNA damage caused by the inhibition of topo IV, would account383
for LVX lethality. The possibility to increase FQs efficacy by elevating the levels of384
intracellular ferrous iron remains open.385
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FIGURE LEGENDS614
FIG 1. Global supercoiling did not vary under treatment of S. pneumoniae R6 (pLS1) with615
levofloxacin. (A) Viability. (B) Topoisomer distribution of pLS1. Exponentially growing616
cultures in AGCH at OD620 = 0.4 were treated with the indicated LVX concentrations.617
Values of a typical experiment are indicated. Samples were taken before the addition of the618
drug (time 0 min), and, at the indicated times, plasmid DNA was isolated and subjected to619
two-dimensional agarose gel electrophoresis run in the presence of 1 and 2 g/ml620
chloroquine in the first and second dimensions, respectively. Supercoiling density ()621
values are indicated. A blackened arrowhead indicates the topoisomer that migrated with622
Lk = 0 in the second dimension that has a Wr = 14. An open arrowhead points to the623
more abundant topoisomer.624
FIG 2. Gene expression analysis in the three conditions assayed. (A and B) Responsive625
genes represented in Venn diagrams with 3 circles, each one corresponding to one time626
interval in each condition, showing the differentially expressed genes in microarrays. (B)627
All genes (left diagram), or only those genes that differed from those present in the No-628
LVX sample (right diagram), are indicated. A complete list of these genes can be found in629
Table 1. (C) Classification of responsive genes by functional classes: CiM, central630
intermediary metabolism; EnM, energy metabolism; Hy, hypothetical proteins; PPy,631
purines, pyrimidines, nucleosides, and nucleotides; Pat, pathogenesis; PrS, protein632
synthesis; R-M, restriction-modification; TBP, transport and binding proteins; TCS, two-633
component systems; Tns, transposon functions; Tr, transcription; U, unclassified; Oth,634
other (classes with a representation < 2%).635
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FIG 3. Transcription of fatD depended on the inhibition of topoisomerase IV by LVX. (A)636
Genetic structure of strain R6-Pfatcat showing the chromosomal location of PfatfatDCEB637
and Pfatcat. Topology-reacting gene clusters detected after DNA relaxation with NOV are638
indicated: U1–15, up-regulated domains; D1–14, down-regulated domains. (B)639
Transcriptional response after NOV treatment measured by qRTPCR on exponentially640
growing cultures of strain R6. (C) Transcriptional response of R6, of a LVX-resistant641
derivative (R6-ParCS79F), and of the R6-Pfatcat strain. Cultures were growth in AGCH to642
OD620 = 0.4, treated with LVX at 0.125 g/ml LVX (0.5 MIC of R6 and R6-Pfatcat; 0.05643
MIC of R6-ParCS79F) and at 2.5 g/ml LVX (10 MIC of R6 and R6-Pfatcat; 0.5 MIC of644
R6-ParCS79F). Total RNA was isolated; cDNA was synthesized and subjected to645
qRTPCR. Data were normalized to time 0 min. Transcription represented the mean of646
qRT-PCR values of three independent replicates  SEM.647
FIG 4. Transcription of fatD depended on the general supercoiling level. Cultures were648
grown as in Fig. 3 and treated with N-methyl-seconeolitsine at the indicated concentrations.649
(A) Plasmid DNA was isolated at the indicated times and subjected to two-dimensional650
agarose gel electrophoresis in the presence of 5 and 15 g/ml chloroquine in the first and651
second dimensions, respectively. Supercoiling density () values are indicated. A black652
arrowhead indicates the topoisomer that migrated with Lk = 0 in the second dimension653
that has a Wr = 30 (53). An open arrowhead indicates the more abundant topoisomer.654
(B) Total RNA was isolated; cDNA was synthesized and subjected to qRTPCR, fatD655
(black bars) and fatC (white bars) values were normalized to time 0 min. Transcription656
represented the mean of qRT-PCR values of three independent replicates  SEM.657
25
FIG 5. LVX lethality is related to the level of intracellular iron. (A) Enzymatic reaction of658
SpxB that renders H2O2, a substrate of the Fenton reaction. P, phosphate. (B) Viability of S.659
pneumoniae R6 (black symbols) or R6spxB (red symbols) either in AGCH, in AGCH plus660
the iron chelator o-phenantroline (AGCH+Ph), in AGCH deficient in SO4Fe (AGCH*).661
Cultures grown as indicated in Fig. 3 in the diverse media were treated, when indicated,662
with LVX at concentrations equivalent to 2.5 MIC. (C) Accumulation of reactive oxygen663
species. Results are the mean  SEM of three independent replicates. RFU, relative664
fluorescence units, values were made relative to 0 min and divided by the number of viable665
cells.666
FIG 6. Oxidative damage cell death pathway. The inhibition of topo IV by levofloxacin667
(LVX) or of topoisomerase I by N-methyl-seconeolitsine (SCN) would cause a local668
increase in supercoiling resulting in the up-regulation of the fatDCEB operon. The669
consequent increase in this iron transporter causes an increase of intracellular ferrous iron670
(Fe2+). This compound and hydrogen peroxide (produced by the activity of the SpxB671
pyruvate oxidase) are the substrates of the Fenton reaction. The Fenton reaction renders672
hydroxyl radicals, which oxidatively damage DNA, proteins and lipids.673
674
26
TABLE 1. Genes involved in the transcriptomic response of S. pneumoniae R6 to675
levofloxacin (LVX)676
677
Role or subrole R6 locus (gene)a Mean relative fold changeb
NO LVX LVX 0.5  MIC LVX 10  MIC
15’ 30’ 5’ 15’ 30’ 5’ 15’ 30’
Amino acid biosynthesis spr0515 (metF)  2.3   2.1   
Biosynthesis of cofactors spr0636      2.0  
spr1438 (entB)        2.2
Cell envelope spr0867 (lytB) 2.9 2.5  3.6 2.7  3.5 3.2
spr1324 (apbE)        2.1
TCS12/ComCDE (°ComE
box)
spr0013° (comX1)  7.8      
spr0020° (comW)  2.5      
spr0043*°0044 (comAB)  3.5      
spr1017° (mreA)  3.0      
spr1819° (comX2)  7.8      
spr1762°  6.0   2.0   
spr2043*°2041 (comC)  8.8   2.4   
(°°ComX box) spr0027°°  2.8      
spr0031*°°0030  4.8   3.0   
spr0128*°°0127 (cibA)  2.7   2.2   
spr0181°° (orf47)  3.6      
spr0856*°°0860 (comEA/EC)  6.9   2.2   
spr0881°° (coiA)  8.3   2.7   
spr0996°° (radC)  6.6   2.3   
spr0997  3.9      
spr1144 (dprA)  5.3   2.1   
spr1628*°°1631 (cclA)  4.5   2.6   
spr1758*°°1756
(cinA/recA/dinF)
 3.1      
spr1831*°°1826  9.2   3.0   2.1
spr1864*°°1855
(cglABCDFG)
 2.5      
spr2006°° (cbpD)  -6.2   2.4   
spr2013*°°2012 (comF/FC)  -11.9   3.0   
TCS13/ SpiRH (SpiR box) spr0040 (pncE)  2.7   2.2   2.0
spr0461  2.1   2.9   2.7
spr0469*0465 (spiABCDP)  2.4  2.2 3.3   2.5
spr0470*0475 (pncW)  3.1  2.2 4.1   3.2
Pathogenesis spr0121 (pspA)        2.6
spr0328 (eng)        2.1
spr0565 (bgaA)        2.6
spr1652*1649 (pfbA)        2.4
Central metabolism spr1867 (nagA)        2.5
spr1833 (bgl2)        2.2
spr1285*1287        2.3
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spr1666 (dpnD)    2.0   2.1 
Energy metabolism spr1029 (glgB)     2.1   2.2
spr0226 (pflE)        2.2
spr1837 (adhE)      2.2  
spr0064 (agaS)        2.5
spr1028 (gapN)      2.5  
spr0065 (galM)        2.2
spr0276     3.8   3.7
spr1647*1648 (galET)       2.0 3.2
spr1668*1667 (galK)  2.7      
spr1974 (fcsR)       2.0 4.1
Protein fate spr1204 (ptrB)     2.0   
Ribosomal proteins
synthesis
spr0078 (rpsD)        2.1
spr1211 (rplL)        2.4
spr0682 (rpsP)        2.4
spr1271 (rpsU)        2.1
spr1943*1944 (rpmFG)        2.0
Purines, pyrimidines,
nucleosides & nucleotides
spr0045*0055 (pur,van, pyr) 8.0 8.1  16.9 15.1  16.2 11.2
spr0613*-0614 2.6   3.8 2.4  3.6 2.8
spr0865*0866 (pyrDIID)    2.5 2.0  2.6 2.4
spr1153 (carB)    2.1 2.1  2.0 
spr1662*1663 (xpt, pbuX)    2.8 3.8  3.1 2.8
spr1709 (gtfA)  2.9      
Transcription spr0634      2.0  
spr0227 (deoR)        2.4
spr0279 (bglG)    3.2 4.1   3.8
spr1067 (lacR)        2.1
spr1439 (codY)        2.0
spr1889        2.8
spr1899 (phoU) 2.3 2.3      
spr1933 (rgg)  3.2      
Transport and binding spr0551 (brnQ)      2.3  2.1
spr0624*0622 (glnQ)       2.1 2.1
spr1895*1898 2.4 2.2      
spr1641 (ctpA)       2.4 2.9
spr1684*1687 (fatDCEB)   3.7 4.7 3.3 3.8 6.2 5.6
spr0264*0265    3.0 2.9  3.0 2.0
spr0278     5.2   4.7
spr0280    2.4 2.6   2.6
spr1710  2.0      
spr1834*1836 (ptcAB)        2.2
spr1836     2.7   3.0
spr0081    2.0    
spr0619 2.5 2.9  2.2 2.2  2.3 2.0
spr0621*0620    2.0 2.0  2.3 2.2
spr1097 (nirC) 2.2 2.1      
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spr1202  2.1      
spr1203  2.1   2.4   
spr1381*1378 2.1   2.2    
spr1441 (oxlT)    3.0 4.3 2.2 3.5 4.0
spr1546  3.7      
spr1646*1643        -2.1
spr1801    3.0 2.8  3.4 2.4
spr1817    -2.0    
Unclassified spr0907*0908 (phtDE)        2.8
spr1060 (phpA)        2.2
Transposon functions spr0018    2.2 2.1   
spr0019     3.1   2.7
spr0041       2.5 
spr0612       2.5 
spr0273  2.6      
spr0523       2.5 
spr1046    2.2    
spr1349*1347 2.4 2.0  2.0    
spr1367 2.4 2.3      
spr1563     2.0   
678
a The responsive genes included showed significant fold variations (2 and P 0.01). All genes showing679
variations, with the exception of 47 encoding hypothetical proteins are included. Genes considered to be680
involved in the LVX-mediated transcriptomic response (i.e., that did not showed variations in the no-LVX681
culture) are shadowed in grey. No shadowed genes are considered to be involved in the growth-related682
response. * indicates the first gene of the putative operon: °gene with a ComE box; °°gene with a ComX box;683
 gene with a SpiR box.684
b In operons, values indicated correspond to those of the first gene of the operon, except in spr00450055,685
spr06130614, spr18591898, spr1864–1855, in which variations corresponded to the second gene. Values686
above 2 are shown in boldface; , no change.687
